SCHEMBL162669

SCHEMBL162669

ClC[C@@H]1CNCCc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 7/20 0.57
HTR2A P28223 6/20 0.57
HTR2B P41595 6/20 0.57
TAAR1 Q96RJ0 2/20 0.53
PRCP P42785 4/20 0.42
ADRB1 P08588 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
CNR1 P21554 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
HRH1 P35367 1/20 0.41
KCNH2 Q12809 1/20 0.41
SLC22A1 O15245 1/20 0.41
PNMT P11086 1/20 0.41
CD44 P16070 1/20 0.41
MAOB P27338 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163850 1.00 HTR2C (0.57) HTR2CHTR2AHTR2BTAAR1PRCP
Bromide SCHEMBL161200 0.98 HTR2C (0.56) HTR2CHTR2AHTR2BTAAR1PRCP
Iodide SCHEMBL162026 0.98 HTR2C (0.56) HTR2CHTR2AHTR2BTAAR1PRCP
Phosphoric Acid SCHEMBL166016 0.91 HTR2C (0.49) HTR2CHTR2AHTR2BTAAR1PRCP
Malonic Acid SCHEMBL160930 0.89 TAAR1 (0.47) HTR2CHTR2AHTR2BTAAR1PRCP
Succinic Acid SCHEMBL161276 0.89 TAAR1 (0.47) HTR2CHTR2AHTR2BTAAR1PRCP
SCHEMBL158569 0.89 HTR2C (0.50) HTR2CHTR2AHTR2BTAAR1PRCP
Nitric Acid SCHEMBL163517 0.89 HTR2C (0.47) HTR2CHTR2AHTR2BTAAR1PRCP
Glycolic Acid SCHEMBL162065 0.89 TAAR1 (0.47) HTR2CHTR2AHTR2BTAAR1PRCP
Fumaric Acid SCHEMBL159722 0.87 TAAR1 (0.46) HTR2CHTR2AHTR2BTAAR1PRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611449-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT Arena Pharmaceuticals, Inc. (US) 2013-07-10 EP disclosed
WO-2012030953-A1 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL ARENA PHARMACEUTICALS, INC. (US) 2012-03-08 WO disclosed
WO-2012030939-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT ARENA PHARMACEUTICALS, INC. (US) 2012-03-08 WO disclosed